NCT06489041 Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
| NCT ID | NCT06489041 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-07-18 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-07-18 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Eligibility Criteria
Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information. * Age ≥ 18 years at the time of consent. * Eligible for standard of care single-gene DPYD testing (i.e., receiving or expected to receive a fluoropyrimidine-based chemotherapy regimen). The potential participant meets inclusion criteria if the standard of care single-gene DPYD test is planned or previously ordered. If previously ordered, consent must occur no later than 60 days from the date the DPYD results were available. * Willing to provide additional buccal swabs if residual DNA from previous DPYD testing is inadequate for microarray testing. Exclusion Criteria: • History of prior allogeneic hematopoietic cell transplantation or liver transplantation
Contact & Investigator
Jai Patel, PharmD
PRINCIPAL INVESTIGATOR
Atrium Health Levine Cancer
Frequently Asked Questions
Who can join the NCT06489041 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06489041 currently recruiting?
Yes, NCT06489041 is actively recruiting participants. Contact the research team at Megan.Lattanze@advocatehealth.org for enrollment information.
Where is the NCT06489041 trial being conducted?
This trial is being conducted at Charlotte, United States.
Who is sponsoring the NCT06489041 clinical trial?
NCT06489041 is sponsored by Wake Forest University Health Sciences. The principal investigator is Jai Patel, PharmD at Atrium Health Levine Cancer. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.